We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Deltex Medical Group Plc | LSE:DEMG | London | Ordinary Share | GB0059337583 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.12 | 0.11 | 0.13 | 0.12 | 0.12 | 0.12 | 189,882 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electromedical Apparatus | 1.78M | -1.28M | -0.0007 | -1.71 | 2.22M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/6/2019 13:48 | Dropping back to supoort at 1.2,shorters piling in | gary38 | |
26/6/2019 13:34 | yes wrong thread good luck to all | manc10 | |
26/6/2019 12:29 | BuywellAre you really trying this twaddle again?Just go back and read the facts I set out last time you tried to troll nonsense about NICEOh and suggest you sell all your beloved LID as they are very exposed to this guideline. Why? 1. Because DEMG's tech proven to work in surgery2. Because LID's tech proven to NOT work during surgery And this will be first time NICE looks at evidence for LID in surgeryNext time at least try something newSchloo | schloo | |
26/6/2019 12:28 | Tit for tat for nobby, so transparent. Or please back up your apprision!! | djgrantb | |
26/6/2019 12:12 | Looks like its heading back support at 1.2 | gary38 | |
26/6/2019 10:31 | schloo I wonder if the selling might have something to do with the ... Publish Date in March 2020 regarding the Perioperative care trial coming ever closer ? '' Once this guideline has published, MTG3 will be withdrawn.” CardioQ-ODM oesophageal doppler monitor (2011) NICE guidance MTG3. MTG3 will be withdrawn when this guideline is published. NICE guideline: Perioperative care in adults Consultation on draft scope Stakeholder comments table 15/11/17 to 13/12/17 Deltex Medical stated on page 5 line number 123 '' Deltex Medical notes that the scope identifies MTG3 as NICE guidance to be “partially&rdq Once this guideline has published, MTG3 will be withdrawn.” NICE/Developer&rsquo ''Thank you for your comment. MTG3 Cardiac monitoring devices will be withdrawn once this new guideline has published. '' I wonder how many probes DEMG sells into the NHS for the ODM MTG3 device ? Quite a lot I would think , probably the majority of probe sales by some margin dyor | buywell3 | |
25/6/2019 17:58 | Buywell You got a number right. Gold star for getting the right number of shares traded Shame you got all the others wrong as it was 10% change, not 12.86% and the closing price is 1.575, not 1.53. but lets start with baby steps and celebrate the one accurate fact More interestingly, there was buying in response to the selling. Not that surprising as these should be at least 3p based on what we know today: DEMG is profitable and cash positive | schloo | |
25/6/2019 16:28 | somebody is selling 1.53 Today's Change -0.225 / -12.86% Shares traded 3.73m | buywell3 | |
24/6/2019 14:34 | Well said BigTGary would have had a better point a few years ago but he is well out of date and totally wrong. DEMG now have TruVue Impedance for awake patients so do have a complete offer and have done for some time now. This troll was off his trolleyMrC | mrc2u | |
24/6/2019 13:58 | gary38, Could you please take your argument re. HUR etc. to that board. Thank you. | bigt20 | |
23/6/2019 22:44 | LOL I am only doing what rayrac is doing....and he is considerably older than me! | nobbygnome | |
23/6/2019 22:37 | How old are you Nobby ? | arab3 | |
23/6/2019 22:11 | However, TrueVue Doppler does not provide a hospital with a complete solution for haemodynamic monitoring as it can be challenging to use on an awake patient where completely non-invasive technologies are preferred.Back to 1p | gary38 | |
23/6/2019 21:57 | It is somewhat amusing that you have taken 2 or 3 days to react to my trolling whereas on the OPTI thread we have put up with rayrac for months and months if not years! | nobbygnome | |
23/6/2019 21:48 | LOL gary38 You are wasting your time here. I will stop trolling the HUR thread if rayrac stops trolling the OPTI thread which he has been doing for years. The standard of his posts there exactly mirror mine on the HUR thread. For example he refuses to accept that the US Pharma is going straight to phase III with LPLDL even though it is a fact. This is because it has the FDA GRAS (generally regarded as safe) designation which means it can be used in food and you can eat as much as you want. So the answer to stop the demolition of the HUR thread is to stop rayrac ruining the OPTI thread. Simples! | nobbygnome | |
23/6/2019 21:47 | This share is starting to atract the traders that smell a good short trade here.1p ,HOW DOES IT FEEL NODDY HAVING TO TASTE YOUR OWN Medicine. | gary38 | |
23/6/2019 21:38 | lower year-on-year revenues attributable, in large part, to substantially reduced expenditure on sales and marketing in H2 2018Back to 1p | gary38 | |
23/6/2019 17:16 | If you go back to August last year, you will see the price has more than doubled since then. There was a day in August where the price touched 0.72p and TC and myself ploughed in and moved the price intraday back up to 0.8p. Since then the price has slowly recovered until now we are sitting on big profits. There are some sad investors on here who could learn about spotting value when it is clearly there. Although patience is required, I think there is clearly more to come here. | nobbygnome | |
20/6/2019 09:36 | Buywell A pathetically ill informed effort even for you as you have quoted the value of the UK revenues rather than the number of units. DEMG mostly place rather than sell their monitors but had one big NHS Trust that bought new monitors in 2018 which was neither expected to be repeated nor was repeated UK probe revenue trend is entirely consistent with each of 2017, 2016, 2015 and 2014 and so neither news nor a surprise. It was early 2014 when the NHS inadvertently pulled its scheme to roll out ODM fully, at pace and scale. This has been bad news for DEMG and very bad news for its shareholders but the impact was only £200,000 last year, whereas it used to be several times higher. It is also part of the reason why those who actually understand the DEMG story think the shares today should be at least 3p, probably 4p. DEMG has weathered a monumental screw up by the NHS and is now profitable and cash positive Well done for picking up a trend five years after it started though | schloo | |
20/6/2019 09:23 | Re: links on this poxy site. Alter the "http" to "hTtp" to get around the prohibition, works most of the time. ie: | maxk | |
20/6/2019 09:10 | There were only 5 new monitors sold in the UK in the last DEMG results Against 92 monitors in the previous year A COLLAPSE in NHS monitor sales For the year ended 31 December 2018 Why do you guys think that happened ? Also only 1,051 probes sold in the UK in the last set of results Against 1354 probes in the previous year , a drop of over 22%. Why was that ? | buywell3 | |
19/6/2019 12:51 | Hi schloo thanks again, I'm no expert but i think if you change the link to https: and not hxxps: readers can click the link to the DEMG website. | gbenson1 | |
19/6/2019 12:36 | And there was this one a while back too hxxps://www.deltexme Starting to feel like NICE is getting its act together to make ODM happen | schloo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions